Loading…
CervoMed Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in CRVO.
▼ -92.5% over 5Y.
today you would have $66.41▼ -93.4%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $7.90 | $2.34 | $7.63 | $7.59 | |
| P/B | 4.0x | 4.0x | 0.5x | 5.9x | — |
| EPS | -$2.98 | -$2.02 | -$0.82 | -$11.20 | |
| ROE | -41.56% | -147.98% | -41.56% | -29.44% | — |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| DCGODocGo Inc. | $0.40 | — | 0.3x | — | -107.79% | $39.32M |
| PAVMPAVmed Inc. | $4.92 | — | 1.0x | — | -64.78% | $39.34M |
| ELUTElutia Inc | $0.88 | — | 2.5x | — | — | $38.97M |
| KPTIKaryopharm Therapeutics Inc. | $1.75 | — |
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodbrain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Company description provided by Yahoo Finance.
| — |
| — |
| — |
| $39.69M |
| CPHIChina Pharma Holdings Inc | $0.90 | — | 1.0x | — | -20.99% | $38.9M |
| ACTUActuate Therapeutics Inc | $1.66 | — | 40.4x | — | — | $39.74M |